Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 33Recurrence 8Lymphoma, Large B-Cell, Diffuse 4Immunoglobulin Light-chain Amyloidosis 4Neoplasms, Plasma Cell 2Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2Sarcoma, Kaposi 1Proteostasis Deficiencies 1Plasmablastic Lymphoma 1Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Epstein-Barr Virus Infections 1Burkitt Lymphoma 1Amyloidosis 1Acquired Immunodeficiency Syndrome 1

Interventions

pomalidomide 1daratumumab 1belantamab mafodotin 1Lenalidomide 1Hyaluronoglucosaminidase 1Dexamethasone 1Cyclophosphamide 1Bortezomib 1Antineoplastic Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Amyloidosis × pomalidomide × Clear all
NCT06376214 2024-04-19

Daratumumab for Patients With Light Chain Amyloidosis

Nanjing University School of Medicine

Phase NA Recruiting
100 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡